Human study PLS-00043

Expression Patterns of MOTS-c in Adrenal Tumors: Results from a Preliminary Study.

Cross-sectional study · Not reported participants enrolled · not included in the assessments (other)

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

Expression Patterns of MOTS-c in Adrenal Tumors: Results from a Preliminary Study.primary · International journal of molecular sciences · 2024-08-09 · PMID 39201408 · DOI

Design and participants

Design: Cross-sectional study
Population: Patients with adrenocortical carcinoma, adrenocortical adenoma or pheochromocytoma, compared with normal adrenal tissue and healthy controls
Conditions: Adrenocortical carcinoma, Adrenocortical adenoma, Pheochromocytoma
Planned enrollment (registry): Not reported
Enrolled: Not reported
Randomized: Not reported
Completed follow-up: Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

What the authors reported

As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

Adverse events

None reported. That is not evidence of safety, and how safety was monitored isn’t described.

The authors concluded (paraphrased): MOTS-c expression is disrupted across adrenal tumors: tissue mRNA and protein are reduced and serum levels are altered. This may reflect mitochondrial dysfunction and tissue changes with disease progression, suggesting a role for mitochondrial-derived peptides in tumor biology.

Peptide Library’s assessment

An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

Limitations

other: Endogenous MOTS-c was measured as a biomarker. The compound was never administered, so the study gives no information on its effects.
abstract only: Only the abstract is available in the record. Sample sizes and methods details are not stated.
inappropriate population: The study measured endogenous MOTS-c in tumor patients and gave no compound, so it cannot inform the intervention claims.

No risk-of-bias assessment has been published for this study’s results.

Claims this study informs

Improves metabolic health: not eligible (not primary study) for “Insulin sensitivity, glucose control or body weight”
Is safe for human administration: not eligible (not primary study) for “Adverse events, serious adverse events and discontinuations”

Where each value comes from

author_conclusion: PMID 39201408, abstract (sentences 9-10) · extracted by AI (automated, not verified by a person) · abstract only
design: PMID 39201408, abstract (sentence 3) · extracted by AI (automated, not verified by a person) · abstract only
population: PMID 39201408, abstract (sentence 3) · extracted by AI (automated, not verified by a person) · abstract only

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).